Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217635 | 0.84 | CYP2D6 (0.37) | CTSSCTSKNOS1NOS3NOS2 | |
| SCHEMBL3400359 | 0.82 | CTSS (0.34) | CTSSCTSKNOS1NOS3NOS2 | |
| SCHEMBL3400364 | 0.82 | CTSS (0.34) | CTSSCTSKNOS1NOS3NOS2 | |
| SCHEMBL3310723 | 0.82 | CTSS (0.34) | CTSSCTSKNOS1NOS3NOS2 | |
| SCHEMBL14405592 | 0.81 | CA1 (0.35) | NOS1NOS3NOS2 | |
| SCHEMBL4607095 | 0.81 | CA1 (0.35) | NOS1NOS3NOS2 | |
| SCHEMBL4607090 | 0.81 | CA1 (0.35) | NOS1NOS3NOS2 | |
| SCHEMBL23709869 | 0.81 | ALDH1A1 (0.33) | — | |
| SCHEMBL12484953 | 0.81 | NOS1 (0.31) | CTSSCTSKNOS1NOS3NOS2 | |
| SCHEMBL2121642 | 0.77 | AAK1 (0.35) | CTSSCTSKNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051706-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM PHARMA CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| CN-103517904-A | Alpha-helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2014-01-15 | — | — | CN | disclosed |
| EP-2678341-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM Pharma Co., Ltd. (JP) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012115286-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051706-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | CTSS 1357/4885CTSK 1924/4885NOS1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.